1. Johnson, R. W. (2010). Herpes zoster and postherpetic neuralgia. Expert Review of Vaccines, 9(3), 21–26. https://doi.org/10.1586/erv.10.30
2. Floß, N., & Dolff, S. (2019). Opportunistische Infektionen durch humane Herpesviren [Opportunistic infections by human herpes viruses]. Der Internist, 60(7), 678–683. https://doi.org/10.1007/s00108-019-0615-6
3. Andrei, G., & Snoeck, R. (2021). Advances and perspectives in the management of Varicella-Zoster Virus infections. Molecules, 26(4), 1132. https://doi.org/10.3390/molecules26041132
4. Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H., Centers for Disease Control and Prevention (CDC), National Institutes of Health, & HIV Medicine Association of the Infectious Diseases Society of America. (2009). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 58(RR-4), 1–207.
5. Panggabean, J. A., Adiguna, S. P., Rahmawati, S. I., Ahmadi, P., Zainuddin, E. N., Bayu, A., & Putra, M. Y. (2022). Antiviral activities of algal-based sulfated polysaccharides. Molecules, 27, 1178. https://doi.org/10.3390/molecules27041178